Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Summit Therapeutics ( (SMMT) ) just unveiled an announcement.
On September 7, 2025, Summit Therapeutics announced promising data from its Phase III HARMONi trial for ivonescimab, presented at the World Conference on Lung Cancer. The trial showed ivonescimab plus chemotherapy improved overall survival in patients with EGFR-mutated non-small cell lung cancer compared to chemotherapy alone, with a notable trend in North American and Western patients. The study highlighted ivonescimab’s potential to change cancer treatment landscapes globally, supported by a manageable safety profile and consistent efficacy across subgroups.
The most recent analyst rating on (SMMT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.
Spark’s Take on SMMT Stock
According to Spark, TipRanks’ AI Analyst, SMMT is a Neutral.
Summit Therapeutics’ stock score reflects significant financial challenges, including lack of revenue and ongoing losses, balanced by a strong equity position. Technical indicators show positive momentum, supporting short-term interest. Valuation remains weak due to negative earnings and no dividend. Positive clinical developments from the earnings call bolster the score, highlighting potential for future growth.
To see Spark’s full report on SMMT stock, click here.
More about Summit Therapeutics
Summit Therapeutics Inc. operates in the biotechnology industry, focusing on developing novel therapies for cancer treatment. The company is engaged in advancing investigational drugs, such as ivonescimab, a bispecific antibody, targeting unmet medical needs in oncology across multiple regions including North America, South America, Europe, the Middle East, Africa, and Japan.
Average Trading Volume: 3,331,474
Technical Sentiment Signal: Strong Buy
Current Market Cap: $19.3B
For detailed information about SMMT stock, go to TipRanks’ Stock Analysis page.